RELATING TO TERMINAL ILLNESSES.

Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions.

Voted 1/26/2026

Roll-call record

How representatives voted

0 yea·0 nay

No roll-call votes recorded for this bill yet.

Docket history

Action history

1/26/2026Referred to HHS, CPN/JDC.
1/21/2026Introduced and passed First Reading.
1/14/2026Pending Introduction.